Novel Target 2

About Antabio

Antabio is a French biotech tackling the global antimicrobial resistance (AMR) crisis by developing innovative antibacterial therapies. Its most advanced asset, Meropenem-Pilabactam (MEM-PIL), is a β-lactam/β-lactamase inhibitor combination in Phase 2 development for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP) and bloodstream infections (BSI). The company is backed by prominent investors like the AMR Action Fund and has a diversified early-stage pipeline targeting chronic respiratory diseases and novel bacterial targets.

Therapeutic Areas

Other Oral/IV, Nosocomial Infections Drugs